Ortho Regenerative Technologies Inc.

ORTH on CSEToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.30CAN -0.01/-3.23%9,0000.16 / 0.807.41 M

Contact Information

Ortho Regenerative Technologies Inc.

Headquarters:
16667 Hymus Blvd.,
Montréal, Québec
Canada, H9H 4R9
Tel: 514-782-0951
Email: Send a message
Website: Visit website
For more information...
Lead: Barry Mire

Ortho RTi is an emerging Orthopaedic and Sports Medicine biologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bioactivity and residency of our proprietary biopolymer, Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com. 

Brent Norton, MD - Chief Executive Officer

Luc Mainville, MBA - Senior VP, Chief Financial Officer

Francois-Xavier Lacasse, PhD. - Vice rpesident of Product Development

Jeff Skinner - Vice President Business Development

Steven Saviuk - Executive Chairman of the Board

Brent Norton, MD - Director

Michael Bushmann - Director

Caroline Hoemann - Director

Tom Wright - Director

Stock Information

Company Overview

Ortho RTi is an emerging Orthopaedic and Sports Medicine biologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bioactivity and residency of our proprietary biopolymer, Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com. 

Management

Brent Norton, MD - Chief Executive Officer

Luc Mainville, MBA - Senior VP, Chief Financial Officer

Francois-Xavier Lacasse, PhD. - Vice rpesident of Product Development

Jeff Skinner - Vice President Business Development

Board of Directors

Steven Saviuk - Executive Chairman of the Board

Brent Norton, MD - Director

Michael Bushmann - Director

Caroline Hoemann - Director

Tom Wright - Director

Contact Information

Headquarters:
16667 Hymus Blvd.,
Montréal, Québec
H9H 4R9, Canada
Telephone: 514-782-0951
Email: Send a message
Website: Visit website